Skip to content

The Effect of Frailty on Balance, Activities of Daily, and Exercise Capacity in COPD

The Effect Of Frailty Level On Balance, Cognition And Activities Of Daily Living In COPD

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03840941
Enrollment
48
Registered
2019-02-15
Start date
2018-03-01
Completion date
2019-10-15
Last updated
2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Frailty

Keywords

COPD, Frailty, Balance, Cognition, Activities of Daily Living

Brief summary

The investigators aim to demonstrate whether balance, cognition and activities of daily living have changed in COPD patients with and without frailty.

Detailed description

COPD is a common, preventable and treatable disease characterized by progressive respiratory symptoms and airflow limitation. Frailty defines a clinical syndrome characterized by multiple system effects, leading to decreased functional reserve and increased sensitivity to dependence or mortality following minor stress events. Inflammation, lack of physical activity, reduced exercise efficiency and maximum oxygen uptake may contribute to the development of frailty in patients with COPD. Balance, cognition and activities of daily living are associated with COPD. This study will evaluate the effect of frailty on balance, cognition and activities of daily living in patients with COPD.

Interventions

None listed

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
55 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* COPD patients who have been clinically stable for the last four weeks and who have not undergone drug change for the last four weeks * Being 55 years of age or older * Accepted to participate in the study (Able and wililing to complete the informed consent process) * Co-operate * Patients with COPD who are ambulant without support or an assistive device

Exclusion criteria

* Neurological, cardiac or orthopedic diseases * Other chronic diseases that may affect balance and walking

Design outcomes

Primary

MeasureTime frameDescription
Perform activities of daily living (ADL) will be evaluated using the Glittre ADL-test1st DayGlittre ADL-test was designed specifically to assess the functional limitation in patients with COPD. Glittre ADL-test time will be considered the main outcome variable, and will be recorded in minutes (metric).
Presence of The Frailty Will Be evaluated Using The Frailty Criteria by Fried1st DayFrailty will be identified by the presence of three or more of the following criteria unintentional weight loss (10 Ibs in past year), weakness (grip strength), self-reported exhaustion, slow walking speed and low physical activity. Patients with three or more of the criteria present were classified as frail.
Balance Assessment Using Functional Reach Test1st DayThe Functional Reach Test measures how far patient can reach forward from a normal relaxed stance.
Cognition Using MoCA-Test1st DayCognitive function will be evaluated with the secreening tool the Montreal Cognitive Assessment (MoCA). The MoCA is a 30-point screening tool.

Secondary

MeasureTime frameDescription
Exercise Capacity Using 6-Minute Walk Test1st DayThe standard protocol of the test is applied in a 30-meter continuous corridor. Standard instructions are given during testing.
Disease-Related Quality of Life Assessment1st DayCOPD evaluation test (CAT) was developed to help assess health status.
Respiratory Muscle Strength Assessment1st DayRespiratory muscle strength will be evaluated by non-invasive methods by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP).
Shortness of Breath Assessment1st DayModified Medical Research Council (mMRC) dyspnea scale will be used to determine the shortness of breath severity.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026